Paradigm Biocapital Advisors LP Tarsus Pharmaceuticals, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.47 Billion
- Q2 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,435,416 shares of TARS stock, worth $115 Million. This represents 2.68% of its overall portfolio holdings.
Number of Shares
2,435,416
Previous 2,863,406
14.95%
Holding current value
$115 Million
Previous $104 Million
36.4%
% of portfolio
2.68%
Previous 3.9%
Shares
3 transactions
Others Institutions Holding TARS
# of Institutions
159Shares Held
40.9MCall Options Held
37.9KPut Options Held
808K-
Rtw Investments, LP New York, NY3.41MShares$161 Million1.55% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$155 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$107 Million7.48% of portfolio
-
Cowen And Company, LLC2.2MShares$104 Million1.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$94.1 Million0.0% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.26B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...